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Severe malaria is associated with decreased nitric oxide (NO) production and low plasma concentrations of
L-arginine, the substrate for NO synthase. Supplementation with L-arginine has the potential to improve NO
bioavailability and outcomes. We developed a pharmacokinetic model for L-arginine in moderately severe
malaria to explore the concentration-time profile and identify important covariates. In doses of 3, 6, or 12 g,
L-arginine was infused over 30 min to 30 adults with moderately severe malaria, and plasma concentrations
were measured at 8 to 11 time points. Patients who had not received L-arginine were also assessed and included
in the model. The data were analyzed using a population approach with NONMEM software. A two-compart-
ment linear model with first-order elimination best described the data, with a clearance of 44 liters/h (coef-
ficient of variation [CV] 52%) and a volume of distribution of 24 liters (CV 19%). The natural time course
of L-arginine recovery was described empirically by a second-order polynomial with a time to half recovery of
26 h. The half-life of exogenous L-arginine was reduced in patients with malaria compared with that for healthy
adults. Weight and ethnicity were significant covariates for clearance. MATLAB simulations of dosing sched-
ules for use in future studies predicted that 12 g given over 6, 8, or 12 h will provide concentrations above the
Km of endothelial cell CAT-1 transporters in 90%, 75%, and 60% of patients, respectively.
The treatment of severe malaria currently relies on antima-
larial drugs and supportive treatments, but the early case fa-
tality rate remains high (8). Adjunctive therapies targeting
underlying pathogenic processes early in the treatment of se-
vere malaria may reduce mortality further, but to date none
have proven efficacious (10). L-Arginine has been proposed as
a potential adjunctive therapy for severe malaria because of its
ability to increase nitric oxide (NO) production in endothelial
and other cells (16, 34).
We have previously described impaired production of NO
(1, 34); low plasma concentrations of its precursor, L-arginine
(16); and impaired NO-dependent endothelial function in
cases of severe malaria (34). Endothelial dysfunction is a mea-
sure of endothelial activation and may play a role in the patho-
genesis of severe malaria by increasing the adhesion of para-
sitized erythrocytes to the endothelium and thereby worsening
microcirculatory obstruction and oxygen delivery (9). NO
downregulates endothelial inflammation (7) and reduces the
cytoadherence of parasitized erythrocytes in vitro (20, 23).
Endothelial NO production is dependent on the intracellular
movement of extracellular L-arginine by cationic amino acid
transporter protein-1 (CAT-1) (35). Estimates for the half-
saturating concentration (Km) of extracellular L-arginine for
CAT-1 are 100 to 150 mol/liter (32), within the estimated
range of the Km of extracellular L-arginine for intracellular NO
production (73 to 150 mol/liter) (11, 14). In severe malaria,
plasma L-arginine concentrations are below this Km, likely con-
tributing to the decreased NO production and endothelial dys-
function found in severe disease. Hypoargininemia also results
in NO synthase production of reactive oxygen species instead
of NO, resulting in an increase in oxidative stress (24, 30). By
infusing L-arginine in patients with moderately severe malaria,
we were able to significantly improve endothelial function (34).
Previous pharmacokinetic studies of the exogenous administra-
tion of L-arginine have been conducted primarily with healthy
adult individuals (4, 5), with no data on pharmacokinetic param-
eters in patients with acute infections such as malaria.
We undertook a prospective observational study to evaluate
the natural time course of the recovery of L-arginine concen-
trations in parallel with a single, ascending-dose study of L-
arginine infusion in adults with moderately severe malaria. A
population pharmacokinetic model was developed, and simu-
lations were carried out to assess the effectiveness of various
regimens of L-arginine infusion to maintain plasma concentra-
tions above the Km of the endothelial cell CAT transporters.
MATERIALS AND METHODS
Study site and subjects. The study was conducted at Mitra Masyarakat Hos-
pital in Timika, Papua, Indonesia, an area with unstable transmission of malaria
and high rates of hospitalization from both falciparum and vivax malaria (15, 21).
Ethical approval was obtained from the Health Research Ethics Committees of
the National Institute of Health Research and Development, Indonesia, and
Menzies School of Health Research, Australia. Written informed consent was
obtained from patients or attending relatives in Indonesian or a local language
when necessary.
Adults older than 18 years with moderately severe falciparum malaria were
enrolled at the emergency department or outpatient clinic (34). Moderately
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severe falciparum malaria was defined as a fever or history of a fever in the past
48 h, with 1,000 asexual Plasmodium falciparum parasites/l of blood (a thresh-
old for clinical falciparum malaria in Papua [26]) in patients with no other
identified etiology who required inpatient parenteral therapy but did not exhibit
the warning signs or criteria for severe malaria as defined by the World Health
Organization (31). The exclusion criteria were being pregnant or breastfeeding,
having been treated with parenteral antimalarials for 18 h prior to admission,
and/or having mixed P. falciparum/Plasmodium vivax infections. Patients were
also excluded if significant comorbidities (including diabetes; known cardiac,
renal or hepatic disease; a concurrent infection[s]; concurrent use of any medi-
cation; a hemoglobin count of 6 g/dl; and/or a systolic blood pressure of 100
mm Hg) or biochemical abnormalities (a baseline venous bicarbonate level of
20 mmol/liter, potassium level of 4.2 mmol/liter, glucose level of 3 mmol/
liter, or chloride level of 106 mmol/liter) were identified. In those receiving
L-arginine, an allergy to L-arginine was an additional exclusion criterion.
Study design. Eligible subjects were enrolled, as described previously, into one
of two groups: an intervention arm receiving intravenous L-arginine or an ob-
servational arm in which the subjects received a similar volume of saline (34).
Enrollment was nonrandomized, with all subjects receiving standard antimalarial
therapy with intravenous quinine (34). There were no significant differences in
the baseline demographic or clinical characteristics between those receiving
saline or L-arginine (34). In the intervention group, three groups of 10 different
patients were given 3 g (17 mmol), 6 g (34 mmol) or 12 g (68 mmol) of L-arginine
diluted in normal saline to a concentration of 10% or less by an infusion pump
over 30 min via an intravenous cannula in the antecubital fossa. All patients gave
a standardized medical history and underwent serial physical examinations. For
the observational study, venous blood was collected into tubes containing lithium
heparin upon recruitment and at regular intervals until discharge. For patients
receiving L-arginine, venous blood was collected before and immediately at the
end of the infusion and repeated at approximately 5, 20, 30, 60, and 120 min and
4, 8, and 24 h after the end of the infusion. Hemoglobin and white blood cell
counts were measured by Coulter counter, and routine biochemistry and acid
base parameters were analyzed with a bedside biochemical analyzer (i-Stat
Corp., Windsor, NJ). Parasite counts were determined by Giemsa-stained thick
and thin fields and were cross-checked by an experienced microscopist.
Determination of plasma concentrations of L-arginine. Plasma was separated
by centrifugation within 30 min of collection and stored at 70°C. Amino acids
were extracted from 50 l of plasma after the addition of 50 l of an internal
standard (norleucine) and 200 l of cold ethanol. Deproteinized plasma was
derivatized with AccQFluor reagent (Waters Corp., Milford, MA), and amino
acids were measured by high-performance liquid chromatography (Shimadzu,
Kyoto, Japan), using a method modified from that of van Wandelen and Cohen
(28). By this method, the percent coefficient of variation (CV%) for L-arginine
was 4.6 at 77 M, with a lower limit of detection of 2.5 M (0.53 mg/liter).
Population pharmacokinetic modeling. Data were analyzed using the first-order
conditional estimation (FOCE) method with interaction in NONMEM (version 5,
level 1.1) with the G77 FORTRAN compiler (3). An evaluation of model suitability
was conducted with standard goodness-of-fit criteria such as measurement of objec-
tive function, parameter estimates, between-subject variability (BSV) and diagnostic
plots (12). The standard three-stage population analysis approach was used to
identify covariates (18). Model selection was based on three further criteria. (i)
Models had to have statistical significance corresponding to a drop in NONMEM
objective function between successive models of 3.84 units (2 test, P  0.05), with
a one-parameter difference between models. (ii) The parameter estimates were
required to be physiologically plausible (e.g., a nonnegative value for clearance or a
central volume less than the plasma volume). This criterion was also applied to
between-subject variance, where extremely small or large values were considered
indicators of overparameterization of the model. (iii) Models had to have stability,
which was assessed by altering the initial parameter estimates and/or changing the
number of significant digits. Neither should affect the final parameter values if the
model is stable. For covariate analysis, additional criteria were also considered: (i)
clinical significance (defined as a change in parameter values of 20% over the
range of the usual values of the covariate); (ii) a biologically plausible relationship;
and (iii) a reduction in random BSV.
Model development. Structural models. Compartmental models were parame-
terized in terms of volume of distribution (V) and clearance (CL). For the natural
recovery of L-arginine, a model was constructed to allow for the effect of the
infection on the turnover of L-arginine concentrations. The assumptions were that
the effects of the infection occurred 48 h prior to admission, resulting in a decrease
in L-arginine concentration until antimalarial treatment was started. This corre-
sponded to the duration of symptoms before patients sought medical help.
Dosing simulations. Stochastic simulations were performed using MATLAB
(version 6.5, release 13) to identify suitable dosing regimens for L-arginine that
maintained the concentrations above the Km of the CAT transporter, set as 150
mol/liter. This was performed by generating the pharmacokinetic profiles of
1,000 virtual subjects under different dosing regimens and assessing the propor-
tion of patients that had concentrations above the Km value.
RESULTS
A total of 78 patients were enrolled, 48 in the observational
group and 30 in the group receiving L-arginine. The patient
characteristics are shown in Table 1.
Safety of L-arginine infusions. L-Arginine infusions were well
tolerated. No new symptoms developed during infusion except
for mild pain at the infusion site, with no evidence of inflam-
mation, in two patients. There were no statistically or clinically
significant effects on pulse rate or respiratory rate before, dur-
ing, or after the infusion of any dose of L-arginine, with con-
tinuous electrocardiography readings remaining normal
throughout (33). The mean systolic and diastolic blood pres-
sures did not change significantly immediately following the 3
g and 6 g arginine infusions. Patients given 12 g had a transient,
statistically but not clinically significant mean decrease in sys-
tolic (5 mm Hg; 95% confidence interval [CI], 3 to 8 mm Hg;
P  0.01) and diastolic (5 mm Hg; 95% CI, 0.5 to 9 mm Hg; P
 0.03) blood pressures measured immediately at the end of
TABLE 1. Baseline characteristics of patients
Characteristic Saline infusion group L-Arginine infusiongroup
Total no. of subjects 48 30
Mean age yr (range)	 28 (18–56) 28 (18–54)
No. (%) of males 32 (67) 20 (67)
Mean wt kg (range)	 58 (43–77) 58 (42–70)
No. (%) of Papuan
highlanders
37 (77) 23 (77)
No. (%) of current
smokers
19 (40) 11 (37)
No. (%) of ex-smokers 7 (14) 4 (13)
Median no. of days of
fever before
presentation (IQR)a
2 (1–5) 2 (1–4)
Mean systolic blood
pressure mm Hg
(range)	
114 (88–152) 109 (90–138)
No. (%) hypertensive
on enrollment
2 0
Mean pulse rate beats/
minute (range)	
86 (56–118) 80 (54–116)
Mean respiratory rate
breaths/minute
(range)	
25 (14–42) 24 (18–32)
Mean temp °C (range)	 36.5 (34.1–39.8) 37 (34.8–40.2)
Mean white blood cell
count 103 l1
(range)	
5.9 (2.6–10.8) 6.2 (2.3–11.7)
Mean hemoglobin count
g/dl (95% CI)	
12.8 (7.1–16.7) 12.3 (7.5–17)
Mean L-arginine plasma
concn mol/liter
(95% CI)	
42 (37–45) 37 (33–43)
Mean lactate concn
mmol/liter (95% CI)	
1.29 (1.1–1.50) 1.5 (1.2–1.8)
Geometric mean
parasite density
l1 (range)	
13,297 (850–127,350) 17,221 (890–281,864)
a IQR, interquartile range.
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the infusion, which returned to baseline thereafter. Changes in
glucose or electrolyte (potassium, phosphate, bicarbonate, pH,
chloride) measurements following infusion were not clinically
important. The full safety profile following L-arginine infusion
has been reported separately (33).
Population pharmacokinetics. L-Arginine concentrations
pre- and postinfusion. Mean baseline L-arginine concentra-
tions in plasma were 42 mol/liter (95% CI, 37 to 45) in the
observational group and 37 mol/liter (95% CI, 33 to 43) in
those who were to receive L-arginine (P  0.32). Mean peak
L-arginine concentrations after the end of the infusions of 3, 6,
and 12 g rose to 288 mol/liter (95% CI, 172 to 405), 809
mol/liter (95% CI, 592 to 1,027), and 1,310 mol/liter (95%
CI, 911 to 1,709), respectively. Conversely, there was no sig-
nificant change in those patients who received saline infusions.
Natural recovery of L-arginine. A turnover model was used
to describe the increase in L-arginine over time in individuals
who did not receive exogenous L-arginine. This model was
defined by the following equations.
ST 1  Emax
E50 A1A1
dA1
dt   Kinf A1
dA2
dt  Kin Kout  ST A2
In this model, ST is the theoretical effect of the infective
process on the elimination of arginine, A1 represents the in-
fective process, Kinf is the first-order rate constant of the de-
cline in the infective process, Emax is the maximum fraction
that the infective process can increase the turnover of L-argi-
nine, E50 is the amount at which this process is at 50% of its
maximum, Kin is the zero-order rate of production of L-argi-
nine, Kout is the first-order rate constant of the loss of arginine,
and A2 is the amount of L-arginine. An instantaneous infective
process initiated 2 days before the patient was enrolled in the
study was assumed. The time chosen was similar to the actual
duration of the symptoms recorded (median, 2 days; range, 1
to 14 days). The infective process then triggered an increased
turnover of L-arginine, probably via increased catabolism from
a variety of metabolic pathways, including arginase, arginine:
glycine amidinotransferase, and NO synthase (19). The model
allowed for L-arginine to be constantly produced from a large
pool not affected by the process and which then returned to
preinfective amounts once the infective process abated. How-
ever, the model was sensitive to initial estimates. An empirical
second-order polynomial was used as the final model.
Arg0i  1 exp(1)
BL
t Arg0i t1 t t2 t2
where Arg0i represents the ith patient’s baseline value of ar-
ginine, i is the difference between an individual’s value of
Arg0 and the average value in the population, 1 is the average
value of Arg0 in the population, t1 and t2 are the coefficients
in the polynomial linking arginine recovery to time, exp rep-
resents the exponential, BL(t) is the baseline value of arginine
concentration at time t, and t is time and is initiated at 2 days
prior to presentation (approximately the start of symptoms). Us-
ing this model, the time to half recovery was 26 h, and the baseline
value of L-arginine was 33 mol/liter with BSV of 43%.
Pharmacokinetics of L-arginine after infusion. For patients
who received L-arginine, the data were best described by a
two-compartment linear model with first-order elimination
and log-normal BSV for the clearance and central volume
compartment. The error model was a combined proportional
and additive residual variance model. The model allowed for
the baseline concentrations and natural recovery of L-arginine
using the second-order polynomial model described for the
natural recovery. The concentration-time profiles for the ob-
served and predicted L-arginine values and the weighted resid-
ual plot are shown in Fig. 1 and 2A, respectively. The half-life
at  phase (t1/2) was 15 min, and the t1/2 was 3.75 h, with
this phase contributing to 40% of the area under the concen-
tration-time curve. By use of estimates obtained from simula-
tions assuming a log-normal distribution, the CV% of t1/2
was 84% and that of t1/2 was 39%.
Incorporation of weight as a covariate for CL and the addi-
tion of an ethnic group (Papuan versus non-Papuan) improved
the model fit significantly, and both were therefore included in
the final model. The final parameter estimates for the covariate
model are summarized in Table 2, and the weighted residuals
are displayed in Fig. 2B. Inclusion of sex and leukocyte and
parasite counts as covariates for clearance and the weight/
ethnic group to the central volume compartment did not im-
prove the model fit. The residual error did not change between
the full and base pharmacokinetic models, but the BSV on CL
decreased by 62%.
Dosing simulations. Using the baseline model, random sim-
ulations were performed with sampling of 1,000 virtual subjects
from the distribution for CL, the volume of the central com-
partment, and baseline L-arginine concentrations. The Km of
the CAT transporters responsible for the intracellular trans-
port of L-arginine was assumed to be 150 mol/liter (26 mg/
liter). Each virtual subject was dosed with one of the following
dosage regimens: (i) 12 g over 1 h; (ii) 12 g by continuous
infusion over 6, 8, and 12 h; or (iii) intermittent infusions of
3 g, 3 g, and 6 g given over 30 min at 4 h intervals, 6 g and 6 g
given over 30 min at 4 h intervals, and 6 g and 6 g given over
2 h at 4-h intervals. Concentration-time courses were calcu-
lated 12 to 16 h postdosing for the various regimens.
Each regimen was assessed for the percentage of patients
above the Km at the end of the infusions. Regimen one pro-
vided concentrations above the Km for 50% of patients at 2 h
and 25% at 3 h after infusion. The long-duration infusions used
in regimen two maintained concentrations just above Km for a
time period about equal to the duration of the infusion. With
12 g of L-arginine, 90%, 75%, and 60% of individuals achieved
the target Km when infused over 6, 8, and 12 h, respectively.
For the multiple-dose regimens, a dosage of 6 g given over 2 h
and repeated 4 h later provided sufficient time above the Km
and attained peak concentrations equivalent to 12 g, constant-
infusion dosing.
DISCUSSION
In this study, the population pharmacokinetic parameters of
endogenous and exogenous L-arginine were estimated for pa-
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tients with moderately severe malaria. Increased oxidation with-
out a compensatory increase in the de novo synthesis of endog-
enous L-arginine has been described for sepsis (2, 29). This work
led investigators to postulate that L-arginine becomes a condition-
ally essential amino acid during acute inflammatory states (2) and
therefore may be required as part of standard nutritional therapy
in severely ill patients with infections or burns. L-Arginine infu-
sion in adults with sepsis results in only very transient hemody-
namic changes (17). These findings suggest that rapid turnover of
L-arginine occurs in patients with acute inflammatory states, al-
though there are no pharmacokinetic data available for ill sub-
jects. Previously published studies of L-arginine pharmacokinetics
FIG. 1. Concentration-time profiles (A to D) and logs of the concentration-time profiles (E to H) of L-arginine before, during, and up to 24 h
after infusion of saline (A and E) or doses of 3 g (B and F), 6 g (C and G), and 12 g (D and H) of L-arginine. The times of the L-arginine infusions
were from 0 to 0.5 h.
4384 YEO ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 Septem
ber 4, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
have been done with healthy volunteers (4, 22, 25, 27), in whom
L-arginine metabolism is likely to differ significantly from that in
acutely ill individuals.
Early L-arginine pharmacokinetic studies (22, 27) were lim-
ited by short sampling periods and insensitive enzymatic and
photometric assays with high coefficients of variation. More-
recent studies have examined the pharmacokinetics after infu-
sions of 6 g and 30 g of L-arginine over 30 min into healthy
volunteers (4, 13, 25). After a 6 g infusion, the mean peak
L-arginine concentration in plasma of 822 mol/liter (4) was
comparable to the mean peak concentration of 809 mol/liter
for patients with malaria. In contrast, doses of 30 g of L-
arginine in healthy volunteers achieved mean plasma concen-
trations of 6,223 to 7,978 mol/liter (4, 13, 25), higher than the
peak of 1,310 mol/liter we observed in patients with malaria.
The results of one of the volunteer studies were analyzed with
a standard two-stage method and reported dose-dependent
pharmacokinetics, with a decreasing half-life and volume of
distribution with the higher dose (4). The authors suggested
that this observation was due to the renal threshold of L-
arginine being exceeded with the larger dose. However, in our
study there was no evidence for nonlinearity at the dosages
used. In healthy individuals, the elimination half-life ranged
from 40 to 60 min (4), while in our study the t1/2 and t1/2
were 15 min and 3.75 h, respectively. Possible explanations for
the different findings include the short sampling times and the
use of noncompartmental analysis in the previous study. This
would serve to limit the previous study analyses to the consid-
eration of a single exponential decay model with a half-life that
would be expected to lie approximately between our two half-
lives. Previous studies with healthy volunteers did not identify
covariates. In contrast, we found that weight and ethnic group
influenced the pharmacokinetics of L-arginine in patients with
moderately severe malaria.
To our knowledge, this is the first study that has explored the
pharmacokinetics of the natural recovery as well as the admin-
istration of exogenous L-arginine in patients with falciparum
malaria or, indeed, any acute inflammatory disease state. In-
flammatory processes are likely to affect L-arginine homeosta-
sis in patients with malaria. Studies with critically ill children
have shown an increase in the oxidation of L-arginine (2), with
no change in flux compared to that for healthy adults, and in
contrast to that for adults with sepsis, who had a decreased flux
(29). In these studies, NO production accounted for 6% of
L-arginine consumption in acutely ill children, compared to
approximately 2 to 3% in septic adults and 4 to 5% in healthy
adult controls. These studies suggest that most of the plasma
L-arginine is metabolized by other enzymatic pathways, includ-
ing those of arginase and arginine:glycine amidinotransferase,
which produce ornithine and creatine, respectively (32). The
increased plasma arginase activity we noted with malaria (34)
is likely to contribute to increased catabolism and the shorter
half-life of L-arginine we found with acute malaria. The differ-
ences in L-arginine metabolism suggest that understanding the
pharmacokinetics of L-arginine during acute malaria is crucial
to modeling the time course of drug exposure and developing
a dosing strategy which may differ from that for healthy indi-
viduals.
In patients with severe malaria, the eventual target group,
we believe the window for L-arginine therapy would be
within the first 24 to 48 h, when the patients are the most
acutely unwell and before the natural recovery from hy-
poargininemia and endothelial dysfunction. This is also the
TABLE 2. Parameter estimates for final covariate model
Parameter Value SE (% CV)
Exogenous L-arginine
CL (liter h1)b 31 17
V1 (liter)c 27 13
V2 (liter)e 21 39
Q (liter h1)d 74 18
8 (allometric constant for CL) 2.46 23
4 (fractional effect of ethnicity) 1.84 17
10 (allometric constant for V1) 0.781 71
CL (% CV)f 32 30
V1 (% CV)g 19 68
Endogenous L-arginine
Arg0a (mol/liter) 33 10
t1
a (mol/liter/h) 0.0612 78
t2
a (mol/liter/h2) 0.000139 84
Arg0 (% CV) 43 43
Residual error
add
h (mol/liter) 0 22
prop
i (CV) 28.6
a For endogenous L-arginine recovery after falciparum malaria infection,
where  t1 and  t2 are the first- and second-order coefficients of the polynomial.
b CL, clearance in first compartment.
c V1, volume of distribution in first compartment.
d Q, clearance in second compartment.
e V2, volume of distribution in second compartment.
f CL, between-subject variance for clearance in first compartment.
g V1, between-subject variance for volume of distribution in first compart-
ment.
h add, standard deviation of the additive component of the residual error.
i prop, standard deviation of the proportional component of the residual
error.
FIG. 2. Weighted residual plots for the baseline two-compartment
first-order elimination model (A) and for the final covariate model (B).
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time window in which the use of artesunate, the most rapidly
parasiticidal drug yet available, has been unable to reduce
early fatality in cases of severe malaria (8). In patients with
severe malaria, L-arginine would be given as a continuous
infusion for the time period required to increase the
L-arginine concentration and increase NO production. With
this background, the other major goal of the study was to
simulate the concentration-time profile of various L-arginine
dosage regimens using the pharmacokinetics model devel-
oped. Sustained production of NO by both immune (6) and
endothelial cells (35) is dependent on the transport of ex-
tracellular L-arginine into cells by CAT with a Km of 70 to
150 mol/liter, and we used 150 mol/liter as the target
concentration. The simulations demonstrated that regimens
of continuous infusion of 12 g over 6, 8, and 12 h would
exceed the Km in 90%, 75%, and 60% of patients at the end
of the infusion, but because of the short half-life, such con-
centrations would be maintained only for the duration of the
infusion. However, simulations of multiple-dosing regimens
also provide other options which would provide satisfactory
L-arginine concentration-time exposures. In the absence of a
combined pharmacokinetic/pharmacodynamic model, we do
not know the optimal dosage regimen.
In conclusion, a study of a single, ascending-dose L-argi-
nine infusion in adults with moderately severe malaria was
conducted, and the dosing regimen was found to be safe,
with no clinically significant adverse effects. The pharmaco-
kinetic parameters estimated were significantly different
from those of previous studies with healthy volunteers. Sim-
ulations of various dosing regimens using these parameters
to maintain L-arginine concentrations above the Km of the
CAT were done. These regimens will be assessed in future
trials with patients with severe malaria to determine the
safety and efficacy of L-arginine as an adjunctive therapy.
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